← board
LFVN
distress 0/10 · well-funded / low risk$6.350%today-56% from 52w high
Revenue
$140M
Liquidity
$12M
Runway
—
Shares 1y
-1%
Price & events
+8.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+2.8%
1W
+2.8%
1M
+28.8%
3M
+5.1%
6M
-53.0%
1Y
+0.1%
2Y
-10.7%
5Y
-21.5%
All
Overview
- Market Cap
- $80.11M
- Volume
- 3.74K
- 52 Week Range
- $4.02 – $14.51
- Total Shares
- 12.62M
- Float Shares
- 8.94M
- Short %
- 18.81%
- % Held by Insiders
- 12.03%
- % Held by Institutions
- 62.32%
- RVOL
- 0.01x
- Beta
- 0.76
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-09-03earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-07Lake StreetBuy → Hold
- 2026-02-18Freedom BrokerBuy
- 2025-11-14Freedom BrokerBuy
- 2025-01-14Craig-HallumBuy
- 2024-12-19Lake StreetBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.